AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Cash and Cash Equivalents

Cash and Cash Equivalents %Chg

Cash and Cash Equivalents Common Size

Short-Term Investments

Short-Term Investments %Chg

Short-Term Investments Common Size

Total Cash and Cash Equivalents

Total Cash and Cash Equivalents %Chg

Total Cash and Cash Equivalents Common Size

Accounts Receivable

Accounts Receivable %Chg

Accounts Receivable Common Size

Total Trade Receivables

Total Trade Receivables %Chg

Total Trade Receivables Common Size

Inventories

Inventories %Chg

Inventories Common Size

Other Current Assets

Other Current Assets %Chg

Other Current Assets Common Size

Total Current Assets

Total Current Assets %Chg

Total Current Assets Common Size

Net Property, Plant & Equipment

Net Property, Plant & Equipment %Chg

Net Property, Plant & Equipment Common Size

Net Intangible Assets

Net Intangible Assets %Chg

Net Intangible Assets Common Size

Goodwill

Goodwill %Chg

Goodwill Common Size

Long-Term Investments

Long-Term Investments %Chg

Long-Term Investments Common Size

Other Long-Term Assets

Other Long-Term Assets %Chg

Other Long-Term Assets Common Size

Total Assets

Total Assets %Chg

Total Assets Common Size

Accounts Payable

Accounts Payable %Chg

Accounts Payable Common Size

Short-Term Debt

Short-Term Debt %Chg

Short-Term Debt Common Size

Current Portion of Leases

Current Portion of Leases %Chg

Current Portion of Leases Common Size

Other Current Liabilities

Other Current Liabilities %Chg

Other Current Liabilities Common Size

Total Current Liabilities

Total Current Liabilities %Chg

Total Current Liabilities Common Size

Long-Term Debt

Long-Term Debt %Chg

Long-Term Debt Common Size

Leases

Leases %Chg

Leases Common Size

Other Long-Term Liabilities

Other Long-Term Liabilities %Chg

Other Long-Term Liabilities Common Size

Total Long-Term Liabilities

Total Long-Term Liabilities %Chg

Total Long-Term Liabilities Common Size

Total Liabilities

Total Liabilities %Chg

Total Liabilities Common Size

Common Stock

Common Stock %Chg

Common Stock Common Size

Additional Paid-in Capital

Additional Paid-in Capital %Chg

Additional Paid-in Capital Common Size

Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income %Chg

Accumulated Other Comprehensive Income Common Size

Retained Earnings

Retained Earnings %Chg

Retained Earnings Common Size

Total Common Shareholders' Equity

Total Common Shareholders' Equity %Chg

Total Common Shareholders' Equity Common Size

Minority Interests and Other

Minority Interests and Other %Chg

Minority Interests and Other Common Size

Total Shareholders' Equity

Total Shareholders' Equity %Chg

Total Shareholders' Equity Common Size

Total Liabilities and Shareholders' Equity

Total Liabilities and Shareholders' Equity %Chg

Total Liabilities and Shareholders' Equity Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Assets	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Cash and Cash Equivalents	8,143	7,058	5,230	5,488	4,797	6,916
Short-Term Investments	39	50	165	166	133	160
Total Cash and Cash Equivalents	8,182	7,108	5,395	5,654	4,930	7,076
Accounts Receivable	14,338	14,168	13,250	12,972	11,879	11,047
Total Trade Receivables	14,338	14,168	13,250	12,972	11,879	11,047
Inventories	6,593	6,467	5,884	5,288	5,662	5,667
Other Current Assets	827	1,196	1,610	1,913	1,684	1,603
Total Current Assets	29,940	28,939	26,139	25,827	24,155	25,393
Net Property, Plant & Equipment	13,783	13,229	12,303	11,647	11,513	10,833
Net Intangible Assets	38,191	37,925	37,550	37,177	39,394	39,426
Goodwill	21,219	21,222	21,130	21,025	21,139	21,060
Long-Term Investments	2,286	2,139	1,900	1,900	2,145	1,871
Other Long-Term Assets	9,037	8,968	7,231	6,459	6,576	5,757
Total Assets	114,456	112,422	106,253	104,035	104,922	104,340

Liabilities	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Accounts Payable	25,028	23,986	22,544	22,465	21,684	20,463
Short-Term Debt	6,174	6,492	3,403	2,337	1,253	5,067
Current Portion of Leases	379	361	355	339	317	292
Other Current Liabilities	2,473	2,697	2,827	2,725	2,672	2,744
Total Current Liabilities	34,054	33,536	29,129	27,866	25,926	28,566
Long-Term Debt	24,700	24,714	26,692	26,506	28,887	27,225
Leases	1,379	1,272	1,196	1,113	1,105	949
Other Long-Term Liabilities	8,352	8,090	8,105	7,679	8,199	8,002
Total Long-Term Liabilities	34,431	34,076	35,993	35,298	38,191	36,176
Total Liabilities	68,485	67,612	65,122	63,164	64,117	64,742

Equity	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Common Stock	388	388	388	388	388	388
Additional Paid-in Capital	35,243	35,238	35,233	35,226	35,203	35,199
Accumulated Other Comprehensive Income	2,044	2,070	2,054	2,012	1,990	2,078
Retained Earnings	8,213	7,023	3,364	3,160	3,138	1,847
Total Common Shareholders' Equity	45,888	44,719	41,039	40,786	40,719	39,512
Minority Interests and Other	83	91	92	85	86	86
Total Shareholders' Equity	45,971	44,810	41,131	40,871	40,805	39,598
Total Liabilities and Shareholders' Equity	114,456	112,422	106,253	104,035	104,922	104,340